News
IUGNF
0.051
NaN%
--
Weekly Report: what happened at IUGNF last week (0422-0426)?
Weekly Report · 6d ago
Imugene Director’s Shareholding Adjustment
TipRanks · 04/23 07:07
Imugene Limited (IUGNF) Gets a Buy from Bell Potter
TipRanks · 04/23 00:06
Weekly Report: what happened at IUGNF last week (0415-0419)?
Weekly Report · 04/22 10:30
Imugene Limited Issues New Equity Securities
TipRanks · 04/19 06:47
Imugene Limited Announces Investor Webinar
TipRanks · 04/17 02:27
Imugene Partners with Kincell for Growth and Savings
TipRanks · 04/15 23:27
Weekly Report: what happened at IUGNF last week (0408-0412)?
Weekly Report · 04/15 10:23
Imugene Limited Announces Securities Cessation
TipRanks · 04/15 08:37
Imugene Limited Issues New Employee Incentives
TipRanks · 04/15 08:37
Imugene Advances Promising Cancer Therapy Trial
Imugene Limited has commenced enrolment for an expansion study targeting bile tract cancer. Positive preliminary results from their MAST trial. FDA has granted Fast Track Designation for VAXINIA virus. The company's shares are down 3% in the last week.
TipRanks · 04/15 00:08
Weekly Report: what happened at IUGNF last week (0401-0405)?
Weekly Report · 04/08 10:27
Imugene’s Breakthroughs Offer Cancer Treatment Hope
TipRanks · 04/08 00:47
Imugene Secures Crucial CF33 Patent in China
TipRanks · 04/04 04:08
Weekly Report: what happened at IUGNF last week (0325-0329)?
Weekly Report · 04/01 10:26
Weekly Report: what happened at IUGNF last week (0318-0322)?
Weekly Report · 03/25 10:28
Weekly Report: what happened at IUGNF last week (0311-0315)?
Weekly Report · 03/18 10:27
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology company. Its Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics has cleared its first cohort. The company is ready to commence combination dosing solid tumour patients with CD19 targeting drug blinatumomab.
Barchart · 03/11 10:39
Weekly Report: what happened at IUGNF last week (0304-0308)?
Weekly Report · 03/11 10:25
Weekly Report: what happened at IUGNF last week (0226-0301)?
Weekly Report · 03/04 10:27
More
Webull provides a variety of real-time IUGNF stock news. You can receive the latest news about Imugene through multiple platforms. This information may help you make smarter investment decisions.
About IUGNF
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.